VMX-C001

DRUG4 trials

Sponsors

VarmX B.V.

Conditions

Blood Loss, SurgicalCoagulation Disorder

Phase 1

Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects

CompletedNCT05152420

VarmX B.V.Coagulation Disorder

Start: 2021-10-29End: 2023-02-03Updated: 2023-06-02

Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant

Active, not recruitingNCT06372483

VarmX B.V.Coagulation Disorder

Start: 2024-02-21End: 2026-08-31Updated: 2024-11-18

Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin

Active, not recruitingNCT06517563

VarmX B.V.Coagulation Disorder

Start: 2024-08-14End: 2026-10-31Target: 16Updated: 2025-09-10

Phase 3

Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.

Not yet recruitingNCT07288489

VarmX B.V.Blood Loss, Surgical, Coagulation Disorder

Start: 2026-03-01End: 2031-01-01Target: 800Updated: 2026-02-27

Related Papers

Phase 1 Study of the Safety and Pharmacodynamics of a Single Dose of Vmx-C001 in Healthy Subjects with and without FXa Direct Oral Anticoagulants

Blood2024-11-05